Clotting Disorders

Clotting Disorders

A collection of features and news articles published in ASH Clinical News related to clotting disorders.

FDA Grants Orphan Drug Designations to Avatrombopag and CLR 131

The FDA has granted orphan drug designations to two therapies for hematologic conditions. The oral thrombopoietin receptor agonist avatrombopag is indicated for the treatment of...

Metabolic Syndrome Predicts Risk of Recurrent VTE in Patients With Newly Diagnosed DVT

Patients with newly diagnosed deep vein thrombosis (DVT) who have components of metabolic syndrome – hypertension, hyperlipidemia, diabetes mellitus, or obesity – have a...
WIB_icon

Peripherally Inserted Central Catheters Sharply Increase Risk of Childhood VTE Events

In children who received central venous catheters, peripherally inserted central catheters (PICCs) appear to be associated with a higher risk of venous thromboembolism (VTE),...

Perspectives on 2019’s New Hematology Drug Approvals

In 2019, the FDA approved several new therapies – or new indications for previously approved therapies – for people living with blood disorders, including...

Updates on ASH Clinical Practice Guidelines in Development

In 2019, the American Society of Hematology (ASH) continued its efforts to develop and publish evidence-based clinical practice guidelines to help practicing hematologists and...

Early Removal of Central Venous Catheters Does Not Increase Risk of PE

Among patients with a hematologic malignancy and central venous catheter–associated upper extremity deep vein thrombosis (UEDVT), removal of catheters within 48 hours did not...
How I Treat In Brief

How I Treat in Brief: Venous Thromboembolism in Sickle Cell Disease

Arun S. Shet, MD, from the NIH’s National Heart, Lung, and Blood Institute, and Ted Wun, MD, from UC Davis Comprehensive Cancer Center in...

FDA Expands Rivaroxaban’s Indication to Include Hospitalized Patients

The U.S. Food and Drug Administration (FDA) approved the direct oral anticoagulant rivaroxaban for the prevention of venous thromboembolism (VTE) in hospitalized, acutely ill...

Representing Hemostasis and Thrombosis: An Interview With Roy Silverstein, MD

2019 American Society of Hematology (ASH) President Roy Silverstein, MD, speaks about the goals of the ASH Working Group on Hemostasis and Thrombosis. What is...
You Make the Call

Reader Responses: How would you treat a patient with a prolonged PTT and antiphospholipid...

Here’s how readers responded to a You Make the Call question about a patient with a prolonged PTT and antiphospholipid antibodies. Disclaimer: ASH does not...
Advertisement

Current Issue

April 2020, Volume 6, Issue 5

This issue examines current immunization guidelines for patients with hematologic disorders, considers medical education amid the coronavirus pandemic, and more.